OP0087 COMORBIDITIES IN HAND OSTEOARTHRITIS PATIENTS: PREVALENCE AND IMPACT ON PAIN AND PAIN SENSITIZATION

Background: Pain is a hallmark symptom of hand osteoarthritis (OA). A subset people with OA display centrally driven pain characteristics. by person-related factors, but how comorbidities are related to the experience undetermined. Changes in pathophysiology and levels for instants low-grade inflammation, might explain link. Objectives: The purpose this study was determine whether burden or individual were associated sensitization persons OA. Methods: These cross-sectional analyses included 282 participants from Nor-Hand study. Comorbidities assessed an index (subscales: Disease, Limitation Treatment, (0-45 scale)) Sangha et al. completed questionnaires; Numeric Rating Scale (NRS) (0-10) all joints (0-10), Australian/Canadian (AUSCAN) subscale (0-20 scale), Western Ontario & McMaster Universities Arthritis Index (WOMAC) (0-20) homunculus (painful joint sites last six weeks, (0-18)). Pressure threshold (PPT, handheld algometer, kg/cm 2 ) at tibialis anterior trapezius Temporal summation (TS) distal radioulnar tapped weighted probe (x10), central sensitization. TS-delta calculated first peak measure fifth tenth tap. Linear regression used examine relations, while adjusted age, sex, body mass education. Results: (89% women, median (IQR) age: 61 (57-66)) showed broad range severity. Most frequent back (n=170, 60%), hypertension (n= 85, 30%), stomach ulcer/abdominal disease (n=62, 22%) depression (n=46, 16%). 281 (99.3%) reported >1 comorbidity other than Mean (SD) value 7.73 (4.25). Higher values statistically significantly greater severity each questionnaire, lower PPT trapezium (borderline significant anterior), TS (Table). Similar results found subscales. Depression, most measures pain. Included same model, remained similar (not shown). No association between Table. B (95% confidence interval per one SD index/subscale) NRS AUSCAN WOMAC knee/hip Painful Trapezium Tibialis Anterior Comorbidity 0.76 (0.12, 0.24 1.61 (0.15, 0.37 2.76 (0.26, 0.50 (0.42, 0.88 -0.38 (-0.15, -0.04 -0.25 (-0.13, 0.01) 0.25 (0.02, 0.11 Disease 0.69 (0.24, 0.52 0.56 (0.16, 0.46 0.89 (0.22, 0.75 1.34 (0.45, 1.02 2.19 (0.66, 1.76 -0.34 (-0.32, -0.06 -0.24 (-0.29, 0.04) 0.23 Treatment (0.18, 0.48 0.58 (0.18 0.49 0.80 (0.19, 1.29 (0.46, 1.06 1.79 (0.47, 1.65 -0.31 -0.44 -0.19 (-0.28, 0.07) 0.22 (0.01, Limitations (0.32, 0.70 0.86 (0.44, 0.81 1.16 (0.51, 1.20 1.58 (0.78, 1,53 3.30 (1.72, 3.13 -0.41 (-0.47, -0.13 -0.26 (-0.41, 0.02) 0.26 (0.04, 0.33 Depression 0.96 (0.29, 1.63 0.66 (-0.04, 1.36) 1.74 3.02 0.99 (-0.38, 2.35 3.43 6.09 -0.36 (-1.00, 0.29) (-1.25, 0.37) 0.02 (-0.50, 0.53) Back (0.38, 1.40 1.10 (0.57, 1.04 (0.08, 2.00 2.90 (1.87,3.93 2.64 (0.65, 4.64 0.08 0.56) 0.84) (-0.17, 0.61) Hypertension 0.64 (0.05, 1.22 0.45 1.06) 1.00 (-0.12, 2.11) 1.32 (0.13, 2.52 2.74 5.05 -0.32 (-0.88, 0.23) -0.28 (-0.97, 0.40) 0.17 0.62) Conclusion: intensity Hypertension, measures. lack relation suggest more important. Disclosure Interests: Elisabeth Mulrooney: None declared, Tuhina Neogi: Hanne Solveig Dagfinrud: Hilde Berner Hammer Speakers bureau: Speaker fee Novartis, Lilly AbbVie, Pernille Steen Pettersen: Torfinn Lødøen Gaarden: Knut Engedal: Tore K. Kvien Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Biogen, Eli Lilly, Gilead, Mylan, Pfizer, Grant/research support from: BMS, MSD, UCB (to institution)., Karin Magnusson: Ida Haugen Pfizer